The drug was formulated into solid lipid nanoparticles (SLNs), with some variants decorated with lactoferrin (Lf) to enhance targeting of MCF-7 breast cancer cells and Ehrlich carcinoma tumors in mice. The gene discussed is LTF; the disease is breast cancer.